Recruitment

Recruitment Status
Completed
Estimated Enrollment
800

Inclusion Criteria

Have an Investigator's Global Assessment (IGA) >=3 at Screening and at Baseline
Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening and at Baseline
Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous treatment)
...
Have an Investigator's Global Assessment (IGA) >=3 at Screening and at Baseline
Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening and at Baseline
Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous treatment)
Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis for at least 6 months before the first administration of study drug
Have an involved body surface area (BSA) >= 10 percent (%) at Screening and at Baseline

Exclusion Criteria

Has previously received guselkumab or ustekinumab
Has unstable cardiovascular disease, defined as a recent clinical deterioration (example [eg], unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
...
Has previously received guselkumab or ustekinumab
Has unstable cardiovascular disease, defined as a recent clinical deterioration (example [eg], unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Currently has a malignancy or has a history of malignancy within 5 years before Screening (with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration, or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study drug administration)

Summary

Conditions
Psoriasis
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Care Provider, Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 99 years
Gender
Both males and females

Description

This is a randomized (assignment of study drug by chance), double-blind (participants nor study staff will know the identity of study drugs), multicenter study to evaluate efficacy and safety of guselkumab for the treatment of participants with moderate to severe plaque-type psoriasis who had an ina...

This is a randomized (assignment of study drug by chance), double-blind (participants nor study staff will know the identity of study drugs), multicenter study to evaluate efficacy and safety of guselkumab for the treatment of participants with moderate to severe plaque-type psoriasis who had an inadequate response to ustekinumab. The study will consist of a screening period, open-label and double-blind treatment periods, and a follow-up period. The treatment period will have 2 phases: an open-label treatment phase during which all participants will receive ustekinumab at Weeks 0 and 4 and a blinded treatment phase during which participants with an inadequate Investigator's Global Assessment response (IGA≥2) to ustekinumab at Week 16 will be randomized to receive either guselkumab or ustekinumab through Week 44. Participants with an IGA response of 0 or 1 (cleared or minimal disease) at Week 16 will continue to receive open-label treatment with ustekinumab every 12 weeks through Week 40. All participants will complete a follow-up phase through Week 52 for efficacy and through Week 60 for safety evaluations. The total duration of the study will be approximately 64 weeks (includes a 4-week screening period). Participants' safety will be monitored throughout the study.

Inclusion Criteria

Have an Investigator's Global Assessment (IGA) >=3 at Screening and at Baseline
Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening and at Baseline
Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous treatment)
...
Have an Investigator's Global Assessment (IGA) >=3 at Screening and at Baseline
Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening and at Baseline
Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous treatment)
Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis for at least 6 months before the first administration of study drug
Have an involved body surface area (BSA) >= 10 percent (%) at Screening and at Baseline

Exclusion Criteria

Has previously received guselkumab or ustekinumab
Has unstable cardiovascular disease, defined as a recent clinical deterioration (example [eg], unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
...
Has previously received guselkumab or ustekinumab
Has unstable cardiovascular disease, defined as a recent clinical deterioration (example [eg], unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Currently has a malignancy or has a history of malignancy within 5 years before Screening (with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration, or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study drug administration)

Locations

Mahlow
La Coruña
Dallas, Texas
San Antonio, Texas
Torun
...
Mahlow
La Coruña
Dallas, Texas
San Antonio, Texas
Torun
Munster
Berlin
Olsztyn
New York, New York
Leipzig
Gdansk
Alicante
Troy, Michigan
Portland, Oregon
Quebec
Taichung
Coral Gables, Florida
Bonn
Nashville, Tennessee
Bialystok
Lodz
Tainan
Boston, Massachusetts
Moncton, New Brunswick
Stavropol
Anyang
Barcelona
Taoyuan
Essen
Lipetsk
Dudley
Halifax, Nova Scotia
Birmingham, Alabama
Witten
Surrey, British Columbia
Seoul
Vancouver, British Columbia
Ocala, Florida
Incheon
Alpharetta, Georgia
Salford
Skokie, Illinois
Poznań
Fremantle
Taipei
Alcorcon
Pittsburgh, Pennsylvania
Chicago, Illinois
Richmond Hill, Ontario
Chelyabinsk
Los Angeles, California
Madrid
Hamburg
Ufa
Montreal, Quebec
Bakersfield, California
Santa Monica, California
Ekaterinburg
Norfolk, Virginia
London
Indianapolis, Indiana
Atlanta, Georgia
Spokane, Washington
Lublin
Woden
St-Petersburg
Buffalo, New York
Woolloongabba
Austin, Texas
Louisville, Kentucky
Łódź
Krakow
Warszawa
Webster, Texas
Johnston, Rhode Island
Arlington Heights, Illinois
Gera
Ajax, Ontario
Wroclaw
Dundee
Poznan
Arlington, Texas
Lübeck
Bydgoszcz
Krasnodar
Victoria Park
Plainfield, Indiana

Tracking Information

NCT #
NCT02203032
Collaborators
Not Provided
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC